CETAPHIL GENTLE CLEAR TRIPLE-ACTION ACNE SERUM- salicylic acid solution 
Galderma Laboratories, L.P.

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

----------

Drug Facts

Active Ingredients

Salicylic Acid 0.5% 

Purpose

Acne treatment

Uses

For the management of acne                 

Warnings

For external use only.

When using this product
■ skin irritation and dryness is more likely to occur if you use another topical acne medication at the same time. If irritation occurs, only use one topical acne treatment at a time. ■ avoid contact with eyes. If contact occurs, rinse eyes thoroughly with water.

Stop use and ask a doctor if
■ irritation becomes severe

Keep out of reach of children.
If swallowed, get medical help or contact a Poison Control Center right away.

Directions

Sensitivity Test for New User: Apply product sparingly to one or two small affected areas during the first 3 days. If no discomfort occurs, follow directions stated below. • clean the skin thoroughly before applying this product. • cover the entire affected area with a thin layer one to three times daily • because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor. • if bothersome dryness or peeling occurs, reduce application to once a day or every other day.

Inactive Ingredients

WATER, GLYCERIN, COCO-CAPRYLATE/CAPRATE, GLUCONOLACTONE, PROPANEDIOL, SODIUM HYDROXIDE, SUCCINIC ACID, PANTHENOL, NIACINAMIDE, LYSOLECITHIN, SCLEROTIUM GUM, ZINC GLUCONATE, PULLULAN, XANTHAN GUM, PANTOLACTONE, CITRIC ACID, SILICA

Questions or comments?

1-866-735-4137

Distributed by:

Galderma Laboratories, L.P.

Fort Worth, TX 76177
USA

All trademarks are the property of their respective owners

cetaphil.com.
P56577-0


Principle Display Panel - 1 FL OZ Carton

084012 P56577-0 GC Treatment Serum 1oz Carton2

NEW

#1 Doctor Recommended
Sensitive Skincare Brand

Cetaphil®                 

GENTLE CLEAR

Triple-Action
Acne Serum
Salicylic Acid Acne Treatment



Treats and prevents acne while
reducing the appearance of
post-acne marks

With PHA, BHA
Prebiotic and Succinic Acid

5 skin sensitivity signs

1 FL OZ (30 mL)









CETAPHIL GENTLE CLEAR TRIPLE-ACTION ACNE SERUM 
salicylic acid solution
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:0299-4135
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Salicylic Acid (UNII: O414PZ4LPZ) (Salicylic Acid - UNII:O414PZ4LPZ) Salicylic Acid5 mg  in 1 mL
Inactive Ingredients
Ingredient NameStrength
Water (UNII: 059QF0KO0R)  
Glycerin (UNII: PDC6A3C0OX)  
Coco-Caprylate/Caprate (UNII: 8D9H4QU99H)  
Gluconolactone (UNII: WQ29KQ9POT)  
Propanediol (UNII: 5965N8W85T)  
Sodium Hydroxide (UNII: 55X04QC32I)  
Succinic Acid (UNII: AB6MNQ6J6L)  
Panthenol (UNII: WV9CM0O67Z)  
Niacinamide (UNII: 25X51I8RD4)  
Lysophosphatidylcholine, Soybean (UNII: CQD833204Z)  
Betasizofiran (UNII: 2X51AD1X3T)  
Zinc Gluconate (UNII: U6WSN5SQ1Z)  
Pullulan (UNII: 8ZQ0AYU1TT)  
Xanthan Gum (UNII: TTV12P4NEE)  
Pantolactone, (R)- (UNII: J288D7O0JS)  
Citric Acid Monohydrate (UNII: 2968PHW8QP)  
Silicon Dioxide (UNII: ETJ7Z6XBU4)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0299-4135-001 in 1 CARTON05/01/2022
130 mL in 1 TUBE; Type 0: Not a Combination Product
2NDC:0299-4135-055 mL in 1 TUBE; Type 0: Not a Combination Product05/01/2022
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC monograph finalpart333D05/01/2022
Labeler - Galderma Laboratories, L.P. (047350186)
Establishment
NameAddressID/FEIBusiness Operations
Fruit of The Earth, Inc.080086802manufacture(0299-4135)

Revised: 4/2022
Document Id: d0eff7bf-d263-4ce4-a565-1f9187f29436
Set id: 3e6eb59f-c523-460e-87ed-750b4a8cacac
Version: 1
Effective Time: 20220427
 
Galderma Laboratories, L.P.